RDRossana DitangcoMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Round Table Discussion: Genuine supply from the providers- Rossana DitangcoView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Round Table Discussion: True demand from the communities- Midnigh PoonkasetwattanaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Population-based PrEP implementation in New South Wales, Australia- Andrew GrulichView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Using a robust incentive-based, peer-centered model to identify new HIV cases among men who have sex with men, transgender women, and people who inject drugs in Cambodia- Dr. R. SophaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Pre-exposure prophylaxis uptake among men who have sex with men at a clinic in Bangkok, Thailand, 2016- Dr. W. WimonsateView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Consideration regarding the service model on pre-exposure prophylaxis for men who have sex with men in the community- Dr. T.H. KwanView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017e-Cascade for real-time monitoring of HIV program- Matthew AveryView Slideset
JTJoseph TuckerMD, PhD, AMSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Online platforms to spur HIV testing- Joseph Tucker, MD, PhD, AMView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Recruiting people into HIV Services: eBooking- Panus Na NakornView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Prevalence of sarcopenia and associated risk factors among HIV-infected individuals receiving suppressive antiretroviral therapy- Dr. R. RajasuriarView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Higher burden of chronic comorbidities among aged hospitalized HIV patients compared to non-HIV infected patients in Japan- Dr. D. RuzickaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2017Assessment of atherosclerotic cardiovascular disease (ASCVD) risks between HIV-infected patients receiving first-line and second-line antiretroviral therapy- Dr. J. TiarukkitsagulView Slideset
